NEUROSENSE THERAPEUTICS LTD.

(NRSN)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
2.130 USD   +5.97%
08/02NEUROSENSE THERAPEUTICS : Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study - Form 6-K
PU
08/02NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
CI
08/02NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Rising in Defensive Afternoon Trade

06/27/2022 | 01:50pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 1.11% 160.35 Delayed Quote.-37.80%
EARGO, INC. 19.91% 1.13 Delayed Quote.-77.84%
NASDAQ COMPOSITE 2.09% 13047.19 Real-time Quote.-16.60%
NEUROSENSE THERAPEUTICS LTD. 5.97% 2.13 Delayed Quote.-13.41%
PFIZER, INC. 3.77% 50.11 Delayed Quote.-15.14%
All news about NEUROSENSE THERAPEUTICS LTD.
08/02NEUROSENSE THERAPEUTICS : Joins EverythingALS Open Innovation Consortium; Set to Enroll US..
PU
08/02NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Pat..
CI
08/02NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Pati..
PR
08/01NEUROSENSE THERAPEUTICS : Report Of Foreign Private Issuer - Form 6-K
PU
07/28NEUROSENSE THERAPEUTICS : and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers ..
PU
07/28NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers..
PR
07/28NeuroSense Therapeutics Ltd. and NeuraLight Collaborate to Detect Amyotrophic Lateral S..
CI
07/18NEUROSENSE THERAPEUTICS : CEO Provides Key Corporate Update Video - Form 6-K
PU
07/18NeuroSense Therapeutics CEO Provides Key Corporate Update Video
PR
06/30Top Midday Gainers
MT
More news
Analyst Recommendations on NEUROSENSE THERAPEUTICS LTD.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -12,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,05x
Yield 2022 -
Capitalization 24,9 M 24,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 11
Free-Float 58,7%
Chart NEUROSENSE THERAPEUTICS LTD.
Duration : Period :
NeuroSense Therapeutics Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROSENSE THERAPEUTICS LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,13 $
Average target price 7,00 $
Spread / Average Target 229%
EPS Revisions
Managers and Directors
Alon Ben-Noon Chief Executive Officer & Director
Or Eisenberg Chief Financial Officer
Mark Wayne Leuchtenberger Chairman
Oron Yacoby-Zeevi Chief Scientific Officer
Ferenc Tracik Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NEUROSENSE THERAPEUTICS LTD.-13.41%25
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968